Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. With this operation, the Group broadens its presence and offer in these countries. Worldwide Air Liquide already supports 2 million people at home living with a chronic disease and has made Home Healthcare activities one of its strategic development priorities.
The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments. With a turnover of more than €10 million in 2023, they are supported by around fifty employees who have joined the Air Liquide Group.
VitalAire, Air Liquide’s international Home Healthcare brand, is already present in Belgium, Luxembourg and the Netherlands. Drawing on its medico-technical expertise, its experience in personalized support for patients and in the development of associated digital services, Air Liquide, through this acquisition, is strengthening its presence and completing its infusion offer in these two countries.
The geographic and therapeutic complementarity of the acquired entities, combined with the professionalism and the operational excellence of the Air Liquide Group’s teams, will facilitate the development of care plans adapted to patients’ needs and profiles.
Diana Schillag, member of Air Liquide’s Executive Committee in charge of Healthcare, Sustainable Development and Procurement, stated: “We are delighted to strengthen our position in those growing markets and to welcome these new patients and employees to Air Liquide. As a major player in Home Healthcare throughout the world, our ambition is to improve the quality of life of patients to best meet their needs at the lowest cost to society, thereby contributing to more efficient and sustainable healthcare systems.”
By Mary Bailey
Source: chemengonline.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.